Literature DB >> 8249076

The clinical and immunological spectrum of American cutaneous leishmaniasis.

J Convit1, M Ulrich, C T Fernández, F J Tapia, G Cáceres-Dittmar, M Castés, A J Rondón.   

Abstract

American cutaneous leishmaniasis is characterized by a spectrum of clinical manifestations. These include localized, often self-healing single lesions, intermediate forms which frequently produce mucosal lesions and often show exaggerated delayed-type hypersensitivity (DTH), and the rare diffuse cutaneous leishmaniasis in which no reaction of protective cell-mediated immunity or DTH can be demonstrated. Clinical, pathological and immunological studies have begun to unravel some of the mechanisms associated with different disease manifestations, dependent on complex interactions between the host immune response, measured in terms of indices including lymphocyte subsets and lymphokines in vitro and within active lesions, and different species of Leishmania.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249076     DOI: 10.1016/0035-9203(93)90030-t

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  40 in total

1.  In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

Authors:  E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 2.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

3.  Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production.

Authors:  J Li; S Sutterwala; J P Farrell
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  T-bet, GATA-3, and Foxp3 expression and Th1/Th2 cytokine production in the clinical outcome of human infection with Leishmania (Viannia) species.

Authors:  Yira Rosalba Díaz; Ricardo Rojas; Liliana Valderrama; Nancy Gore Saravia
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

5.  Serodiagnosis of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica in Sanliurfa Province, Turkey, where ACL Is highly endemic.

Authors:  Fadile Yildiz Zeyrek; Metin Korkmaz; Yusuf Ozbel
Journal:  Clin Vaccine Immunol       Date:  2007-08-29

6.  Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice.

Authors:  Hamid Mahmoudzadeh-Niknam; Simin Sadat Kiaei; Davood Iravani
Journal:  Korean J Parasitol       Date:  2007-06       Impact factor: 1.341

7.  Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans.

Authors:  Y A Skeiky; D R Benson; J A Guderian; J A Whittle; O Bacelar; E M Carvalho; S G Reed
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

8.  Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy.

Authors:  M Ulrich; V Rodriguez; M Centeno; J Convit
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

9.  Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis.

Authors:  Jiaxiang Ji; Jiaren Sun; Lynn Soong
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives.

Authors:  Luiz Antônio Dutra; Letícia de Almeida; Thais G Passalacqua; Juliana Santana Reis; Fabio A E Torres; Isabel Martinez; Rosangela Gonçalves Peccinini; Chung Man Chin; Konstantin Chegaev; Stefano Guglielmo; Roberta Fruttero; Marcia A S Graminha; Jean Leandro dos Santos
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.